European Union

#European Commission #European Union #Muscular dystrophy

Approval makes spinal muscular atrophy cream available in EU 

The European Commission (EC) has approved Itvisma (onasemnogene abeparvovec) for the treatment of spinal muscular atrophy (SMA).  Itvisma can now be used in the European Union by children two years and older, teens and adults living with 5q SMA with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene.  The… Read More

#News #Regulatory

#Biosimilars #Cancer research #Cancer Research Horizons #Cerebral Palsy #Clinical trial #Crohn's disease #Depression #European Union #Novo Nordisk #Obesity #Psychedelics #Thermo Fisher Scientific #Ulcerative colitis (UC)

DDW Highlights: 24 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers found an unexpected drug could help treat depression. Elsewhere, a new company is… Read More

#Podcasts

#Biosimilars #Cancer research #Cancer Research Horizons #Cerebral Palsy #Clinical trial #Crohn's disease #Depression #European Union #Novo Nordisk #Obesity #Psychedelics #Thermo Fisher Scientific #Ulcerative colitis (UC)

This week in Drug Discovery (16 – 20 February) 

News round-up for 16 – 20 February by Bruno Quinney, Content Team at DDW.  This week in DDW, an unexpected drug could help treat depression. Elsewhere, a new company is set to advance a cerebral palsy therapy.  The top stories:    Psychedelic drug could help treat depression … Read More

#News

#ABPI #Biomanufacturing #Cancer research #Clinical trial #Diabetes #European Union #FDA #Fujifilm #Oncology #Priority Review #Rare diseases #RNA #UK

DDW Highlights: 17 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers made a key discovery into cancer survival. Elsewhere, a global research effort… Read More

#Podcasts

#ABPI #Biomanufacturing #Cancer research #Clinical trial #Diabetes #European Union #FDA #Fujifilm #Oncology #Priority Review #Rare diseases #RNA #UK #United States

This week in Drug Discovery (9 – 13 February) 

News round-up for 9 – 13 February by Bruno Quinney, Content Team at DDW.  This week in DDW, researchers have made a key discovery into cancer survival. Elsewhere, a global research effort into kidney disease is underway.  The top stories:    Researchers identify RNA linked to cancer… Read More

#News

Kidneys
#BioMed X #Diabetes #European Union #Kidney disease

Global research launched into early diabetic kidney disease 

Pharma innovation hub BioMed X has partnered with the government of Barbados to launch global research into a therapy for early diabetic kidney disease.  The new global call for research proposals, entitled ‘AI-Enabled Therapy of Early Diabetic Kidney Disease in Barbados’, addresses the biological heterogeneity of early diabetic kidney disease in the Barbadian population. Read More

#Business & Investment #News

#Drug discovery #European Medicines Agency #European Union #Regulatory

104 new drugs approved in Europe in 2025

In 2025, the European Medicines Agency (EMA) recommended 104 medicines for marketing authorisation, 38 of which had a new active substance which had never been authorised in the European Union (EU) before.   These included the first medicine to treat non-cystic fibrosis bronchiectasis, a first-in-class treatment to delay the onset of… Read More

#News #Regulatory

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

DDW Highlights: 23 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated… Read More

#Podcasts

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

This week in Drug Discovery (15 – 19 December) 

News round-up for 15 – 19 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated antibodies have been tolerated by human immune cells.  The top stories:    Scientists discover hidden molecular switch that… Read More

#News

Woman with a nose bleed
#Amgen #AstraZeneca #European Union

Tezspire approved in EU for ‘challenging’ rhinosinusitis  

AstraZeneca and Amgen’s Tezspire (tezepelumab) has been approved in the European Union for chronic rhinosinusitis with nasal polyps.  Tezspire has been approved as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to standard… Read More

#News #Regulatory

#Europe #European Union #Precision medicine

EU backs Swiss Rockets Serbia precision medicine hub

Biotech company Swiss Rockets Serbia has signed a Joint Declaration of Intent with the European Commission (DG ENEST) and the Development Agency of Serbia (RAS) to establish a regional centre of excellence for precision medicine.  The joint declaration announces the ambition of Swiss Rockets Serbia, a subsidiary of Swiss Rockets… Read More

#Business & Investment #News

European biotech
#Biologics / Biotechnology #Biotech #Europe #European Commission #European Union

Is the European Biotech Act a one-shot solution for the biotech sector?

For European Biotech Week, Diana Turner and Dr Claire Skentelbery, Director General, EuropaBio, examine the potential impact of the European Biotech Act. The European Biotech Act was first introduced by Ursula von der Leyen in 2024 in her paper ‘Europe’s Choice: Political Guidelines For The Next European Commission 2024−2029’. She… Read More

#Exclusive Content #Trends & Analysis

#European Union #GlobalData #Pharmaceutical industry #Politics #United States

Experts weigh the impact of Trump’s proposed tariff on pharma

The pharmaceutical industry is on high alert as US President Donald Trump proposes a 200-250% tariff on drug imports, which could significantly increase prices and reduce profit margins.   While the tariffs are set to be announced soon, a grace period of 12 to 18 months has been indicated before they… Read More

#Business & Investment #News #Trending News

Antibiotics
#Antibiotics #Antimicrobial resistance (AMR) #European Union

AMR will cost $187b more every year without EU investment

An investment of $1 billion to increase access to innovative antibiotics and high-quality treatment of antimicrobial resistance (AMR), could boost the European Union’s (EU) economy by $88 billion a year, by the year 2050.  This is according to new research from the Center for Global Development, the… Read More

#News

Map of Europe
#Clinical trials #EFPIA #Europe #European Commission #European Union

Group warns European clinical research is at risk

A broad group of 14 organisations, working in the European clinical trial sector, have issued a warning that without urgent implementation of the Life Science Strategy (LSS), Europe’s clinical trial eco-system is in a perilous situation.  The stakeholders—including academic and industry sponsors, investigators, and professional societies—formed earlier this year to… Read More

#Business & Investment #News

European Commission President Ursula von der Leyen
#Biotech #Biotech hubs #Europe #European Commission #European Union #Market reporting

Can Europe take the lead on biotech?

With uncertainty across the global financial markets and research community, is it Europe’s time to take the lead on biotech? Diana Turner reports.  While biotech has so far been dominated by the US, since the inauguration of Donald Trump in January 2025, there has been considerable uncertainty, with significant cuts… Read More

#Exclusive Content #Market Reports #Trends & Analysis